ELVN NASDAQ
Enliven Therapeutics, Inc.
1W: +7.2%
1M: -7.3%
3M: -22.8%
YTD: +167.0%
1Y: +101.9%
3Y: +226.9%
5Y: +175.9%
$43.69
+2.20 (+5.30%)
After Hours: $43.28 (-0.41, -0.93%)
Weekly Expected Move ±6.8%
$36
$39
$42
$44
$47
Credit Risk of going bust: lower than 83% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Enliven Therapeutics, Inc. would be worth roughly what it owes.
Total debt $1.5M against a stock market value of $3.04B.
Distance to default 10.59 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.1M (short-term plus half of long-term), stock volatility 73.1%; Altman Z'' 66.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Enliven Therapeutics, Inc. would be worth roughly what it owes.
Total debt $1.5M against a stock market value of $3.04B.
Distance to default 10.59 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.1M (short-term plus half of long-term), stock volatility 73.1%; Altman Z'' 66.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Cash Flow Trends
Operating Cash Flow
-$70M
+3.9% ▲
Capital Expenditures
$158K
-259.1% ▼
5Y CAGR: -19.3%
Free Cash Flow
-$70M
+3.8% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$25M
-205.4% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$25M | -$38M | -$72M | -$89M | -$104M |
| Depreciation & Amort. | $115K | $215K | $297K | $317K | $263K |
| Stock-Based Comp. | $2M | $3M | $13M | $20M | $34M |
| Change in Working Capital | $4M | $438K | $1M | -$5M | -$1M |
| Other Non-Cash Items | $4M | $2M | -$4M | -$118K | $232K |
| Operating Cash Flow | -$19M | -$32M | -$61M | -$73M | -$70M |
| — Investing Activities — | |||||
| Capital Expenditures | -$191K | -$612K | -$149K | -$44K | -$158K |
| Acquisitions (Net) | $0 | $35M | $0 | $0 | $0 |
| Investment Purchases | -$48M | -$35M | -$268M | -$351M | -$447M |
| Investment Sales | $46M | $42M | $120M | $314M | $273M |
| Other Investing | $2M | -$42M | $0 | $873K | $213K |
| Investing Cash Flow | -$191K | -$612K | -$148M | -$36M | -$174M |
| — Financing Activities — | |||||
| Net Debt Issuance | $0 | $0 | $0 | $0 | $0 |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | $0 | -$566K | $73M | $94M | $0 |
| Financing Cash Flow | -$1M | -$2M | $234M | $133M | $219M |
| Net Change in Cash | -$20M | -$34M | $25M | $24M | -$25M |
| Cash End of Period | $110M | $76M | $100M | $124M | $99M |
| Free Cash Flow | -$19M | -$33M | -$61M | -$73M | -$70M |